Not medical advice. I am a software engineer, not a physician. This page documents my own protocol and the research I read while building it. Talk to a qualified clinician before changing your supplementation, diet or any treatment. Lab reference ranges quoted here vary by laboratory and by individual.
Affiliate disclosure: the iHerb links on this page carry a referral code and pay me a commission if you buy. It does not change your price, and I do not link anything I do not use myself.
The pancreas is a dual-function organ with both exocrine (digestive enzyme production) and endocrine (hormone secretion) roles. Its endocrine function — centered in the Islets of Langerhans — is critical for blood sugar regulation. Beta cells produce insulin (lowers blood glucose), while alpha cells produce glucagon (raises blood glucose). This insulin-glucagon axis maintains blood sugar within a narrow range (70-100 mg/dL fasting) that is essential for brain function, energy metabolism, and cellular health.
Insulin resistance — when cells become less responsive to insulin's signal — is the earliest detectable metabolic abnormality on the path to type 2 diabetes, often preceding elevated fasting glucose by 10-15 years. During this silent phase, the pancreas compensates by producing more insulin (hyperinsulinemia), which drives fat storage, inflammation, and hormonal disruption long before blood sugar tests appear abnormal.
Fasting insulin is the early warning: Standard medical practice tests fasting glucose and HbA1c, but these only become abnormal after years of compensated insulin resistance. Fasting insulin is abnormal much earlier — an optimal fasting insulin of <5 uIU/mL indicates excellent sensitivity, while levels >10 uIU/mL suggest developing resistance even with normal glucose. HOMA-IR (Fasting Insulin x Fasting Glucose / 405) provides a calculated insulin resistance score.
Blood sugar regulation is a dynamic system where insulin and glucagon act as opposing signals, with muscle, liver, and adipose tissue as the primary targets. Understanding this system reveals why specific supplements can meaningfully improve glucose metabolism.
Yin, J., et al. (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism, 57(5), 712-717. PubMed 18442638
These supplements improve glucose metabolism through complementary mechanisms: AMPK activation, absorption blunting, and enhanced muscle glucose uptake.
| Supplement | Role | Timing | Details |
|---|---|---|---|
| Berberine | Activates AMPK; reduces HbA1c 0.5-0.9% and fasting glucose 15-25 mg/dL; comparable to metformin | 500 mg 2-3x/day before meals | Berberine |
| Fiber (Psyllium / Glucomannan) | Slows glucose absorption; reduces postprandial spikes by 20-40%; feeds beneficial gut bacteria | 5-10 g/day before carb-rich meals | Prebiotic Fiber |
| Creatine Monohydrate | Enhances GLUT4 translocation; improves insulin-independent glucose uptake in muscle | 5 g/day (synergistic with resistance training) | Creatine |
| Curcumin | Reduces pancreatic inflammation and beta cell oxidative stress; improves insulin sensitivity through NF-kB inhibition | 500-1000 mg/day with piperine and fat | Curcumin |
| Omega-3 (EPA/DHA) | Reduces systemic inflammation that drives insulin resistance; improves beta cell function and lipid profiles | 2-4 g/day with meals | Omega-3 |
Berberine is nature's metformin: A 2008 landmark study showed berberine reduced HbA1c as effectively as metformin (0.9% vs 0.9%) in type 2 diabetic patients. It works through AMPK activation, the same pathway targeted by metformin. Unlike metformin, berberine also has antimicrobial and lipid-lowering properties. Take with meals to minimize GI side effects.
The progression from normal glucose metabolism to type 2 diabetes takes 10-15 years. These tests detect problems at different stages, from earliest insulin resistance to established diabetes.
| Test | What It Measures | Frequency | Details |
|---|---|---|---|
| Fasting Glucose | Blood sugar after 8-12h fast; optimal <90 mg/dL, prediabetes 100-125 mg/dL | Every 6-12 months | Lab Tests |
| HbA1c (Glycated Hemoglobin) | Average blood sugar over 2-3 months; optimal <5.3%, prediabetes 5.7-6.4% | Every 6-12 months | Lab Tests |
| Fasting Insulin | Earliest marker of insulin resistance; optimal <5 uIU/mL, concerning >10 uIU/mL | Every 6-12 months | Lab Tests |
| OGTT (Oral Glucose Tolerance Test) | 2-hour glucose response to 75g glucose load; reveals postprandial dysfunction invisible to fasting tests | Every 12-24 months (if indicated) | Lab Tests |
| Insulin at 2 hours (with OGTT) | Post-load insulin; reveals compensatory hyperinsulinemia and beta cell strain | With OGTT | Lab Tests |
Fasting glucose is the last marker to go abnormal: The progression is: (1) Fasting insulin rises (earliest, often 10+ years before diagnosis), (2) Postprandial glucose becomes abnormal (OGTT), (3) HbA1c creeps up, (4) Fasting glucose finally exceeds 100 mg/dL. If you only test fasting glucose, you are detecting the problem at the latest possible stage. Add fasting insulin to catch it early.
GLP-1 agonist + harmine combination regenerates human beta cells. A breakthrough study published in Science Translational Medicine demonstrated that combining a GLP-1 receptor agonist with a DYRK1A inhibitor (harmine) potentiates functional human beta cell regeneration in cadaveric pancreatic islets, with a relatively beta cell-specific effect. Separately, researchers discovered that pancreatic alpha cells naturally produce far more bioactive GLP-1 than previously thought, directly linked to insulin secretion. These findings open the door to restoring endogenous insulin production in type 2 diabetes rather than merely managing it.
GLP-1 resistance biomarker identified — 1 in 10 may be non-responders. A Stanford meta-analysis (April 2026) across three trials with 1,119 participants identified PAM gene variants associated with reduced GLP-1 drug responsiveness, affecting approximately 10% of people. Those with PAM variants were less successful in lowering HbA1c despite standard dosing. Additionally, PET imaging using an 18F-labeled GLP-1 receptor tracer now enables noninvasive, quantitative assessment of residual beta cell mass in type 1 diabetes, with pancreatic tracer uptake inversely correlated with HbA1c and insulin dose — providing a new biomarker for disease staging.